190 related articles for article (PubMed ID: 22543678)
41. Peginterferon alph-2b (Sylatron) for melanoma.
Med Lett Drugs Ther; 2011 Sep; 53(1373):76. PubMed ID: 21921873
[No Abstract] [Full Text] [Related]
42. BRAF Inhibitor-Induced Antitumoral Granulomatous Dermatitis Eruption in Advanced Melanoma.
Garrido MC; Gutierrez C; Riveiro-Falkenbach E; Ortiz P; Rodriguez-Peralto JL
Am J Dermatopathol; 2015 Oct; 37(10):795-8. PubMed ID: 26381028
[TBL] [Abstract][Full Text] [Related]
43. Depression in hospitalized patients with malignant melanoma treated with interferon-alpha-2b: primary to induced disorders.
Navinés R; Gómez-Gil E; Puig S; Baeza I; De Pablo J; Martín-Santos R
Eur J Dermatol; 2009; 19(6):611-5. PubMed ID: 19709980
[TBL] [Abstract][Full Text] [Related]
44. Inflammatory reaction presages response in melanoma skin lesions during i.m. rIFN alpha-2a-based treatment.
Bracarda S; Roila F; Basurto C; Tonato M
Ann Oncol; 1990 Sep; 1(5):381. PubMed ID: 2148107
[No Abstract] [Full Text] [Related]
45. Low doses interferon-alpha in the treatment of high-risk cutaneous melanoma. Melanoma Cooperative Group.
Ascierto PA; Palmieri G; Strazzullo M; Daponte A; Botti G; Satriano SM; Motti ML; Mozzillo N
Ann Oncol; 2000 Apr; 11(4):487-90. PubMed ID: 10847472
[No Abstract] [Full Text] [Related]
46. Prospective randomized trial of interferon alfa-2b and interleukin-2 as adjuvant treatment for resected intermediate- and high-risk primary melanoma without clinically detectable node metastasis.
Hauschild A; Weichenthal M; Balda BR; Becker JC; Wolff HH; Tilgen W; Schulte KW; Ring J; Schadendorf D; Lischner S; Burg G; Dummer R
J Clin Oncol; 2003 Aug; 21(15):2883-8. PubMed ID: 12885805
[TBL] [Abstract][Full Text] [Related]
47. [A pilot study of low dose alpha-2b interferon in metastatic malignant melanoma with predominant subcutaneous metastases].
Popov I; Jelić S; Kovcin V
Srp Arh Celok Lek; 1995; 123(1-2):5-7. PubMed ID: 17974467
[TBL] [Abstract][Full Text] [Related]
48. Vemurafenib-induced eccrine squamous syringometaplasia.
Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
[TBL] [Abstract][Full Text] [Related]
49. Severe hypotension following inadvertent intravenous administration of interferon alfa-2a.
Hanson DS; Leggette CT
Ann Pharmacother; 1997 Mar; 31(3):371-2. PubMed ID: 9066950
[No Abstract] [Full Text] [Related]
50. Severe action tremor related to interferon-alpha 2b therapy for malignant melanoma.
Nishihori T; Abdo-Matkiwsky M; Fleishman SB; Blum RH
Am J Clin Oncol; 2005 Oct; 28(5):526. PubMed ID: 16199995
[TBL] [Abstract][Full Text] [Related]
51. Cutaneous side effects of combined therapy with sorafenib and pegylated interferon alpha-2b in metastatic melanoma (phase II DeCOG trial).
Degen A; Weichenthal M; Ugurel S; Trefzer U; Kilian K; Garbe C; Egberts F; Poppe LM; Hauschild A; Gutzmer R
J Dtsch Dermatol Ges; 2013 Sep; 11(9):846-53. PubMed ID: 23879405
[TBL] [Abstract][Full Text] [Related]
52. Toxicity of adjuvant high-dose interferon-alpha-2b in patients with cutaneous melanoma at high risk of recurrence.
Schachter J; Brenner B; Fenig E; Yahav J; Marshak G; Sulkes A; Gutman H
Oncol Rep; 1999; 6(6):1389-93. PubMed ID: 10523717
[TBL] [Abstract][Full Text] [Related]
53. Dermoscopy, reflectance confocal microscopy and immunohistochemical analysis in melanocytic lesions with Meyerson's phenomenon.
Oliveira A; Arzberger E; Massone C; Fink-Puches R; Zalaudek I; Hofmann-Wellenhof R
Dermatology; 2014; 229(4):297-305. PubMed ID: 25472722
[TBL] [Abstract][Full Text] [Related]
54. [Recombinant interferon alfa-2b in the treatment of patients with skin melanoma].
Korovin SI
Lik Sprava; 1998; (2):139-41. PubMed ID: 9670687
[TBL] [Abstract][Full Text] [Related]
55. Autoimmunity aids survival in melanoma.
Senior K
Lancet Oncol; 2006 Apr; 7(4):289. PubMed ID: 16598882
[No Abstract] [Full Text] [Related]
56. Interstitial pneumonitis and lung fibrosis during adjuvant treatment of melanoma with interferon alpha according to the Kirkwood schedule.
Puente Vázquez J; Moreno Antón F; Grande Pulido E; López Tarruella-Cobo S; Pérez Segura P; Díaz-Rubio E
Dermatology; 2005; 210(3):247-9. PubMed ID: 15785060
[No Abstract] [Full Text] [Related]
57. [After removal of a malignant melanoma. Enhancing the immune system!].
MMW Fortschr Med; 1999 Nov; 141(44):66. PubMed ID: 10912153
[No Abstract] [Full Text] [Related]
58. Generalized lymphadenopathy mimicking malignant lymph node metastases after interferon-α2b therapy for melanoma.
Yune S; Jang KT; Jung SM; Kim JH; Lee J
Melanoma Res; 2013 Aug; 23(4):336-9. PubMed ID: 23777872
[TBL] [Abstract][Full Text] [Related]
59. Phase III trial comparing adjuvant treatment with pegylated interferon Alfa-2b versus observation: prognostic significance of autoantibodies--EORTC 18991.
Bouwhuis MG; Suciu S; Testori A; Kruit WH; Salès F; Patel P; Punt CJ; Santinami M; Spatz A; Ten Hagen TL; Eggermont AM
J Clin Oncol; 2010 May; 28(14):2460-6. PubMed ID: 20385998
[TBL] [Abstract][Full Text] [Related]
60. Adjuvant interferon therapy for melanoma: high-dose, low-dose, no dose, which dose?
Schuchter LM
J Clin Oncol; 2004 Jan; 22(1):7-10. PubMed ID: 14665612
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
